MCL-1 inhibition in cancer treatment

MCL-1 inhibition in cancer treatment

Weiguo Xiang,1 Chao-Yie Yang,1,2 Longchuan Bai1,2 1Department of Internal Medicine, University of Michigan Medical School, 2Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA Abstract: Myeloid cell leukemia-1 (MCL-1), a member of antiapoptotic BCL-2 family proteins, is a key regulator...

Full description

Bibliographic Details
Main Authors: Xiang W, Yang CY, Bai L
Format: Article
Language:English
Published: Dove Medical Press 2018-10-01
Series:OncoTargets and Therapy
Subjects:
BCL-2
BAX
BAK
apoptosis
BH3 mimetics
Online Access:https://www.dovepress.com/mcl-1-inhibition-in-cancer-treatment-peer-reviewed-article-OTT
id doaj-b8b8f510c56845c3b2e74d46991577df
record_format Article
spelling doaj-b8b8f510c56845c3b2e74d46991577df2020-11-25T01:25:56ZengDove Medical PressOncoTargets and Therapy1178-69302018-10-01Volume 117301731441638MCL-1 inhibition in cancer treatmentXiang WYang CYBai LWeiguo Xiang,1 Chao-Yie Yang,1,2 Longchuan Bai1,2 1Department of Internal Medicine, University of Michigan Medical School, 2Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA Abstract: Myeloid cell leukemia-1 (MCL-1), a member of antiapoptotic BCL-2 family proteins, is a key regulator of mitochondrial homeostasis. Frequent overexpression of MCL-1 in human primary and drug-resistant cancer cells makes it an attractive cancer therapeutic target. Significant progress has been made in the development of small-molecule MCL-1 inhibitors in recent years, and three MCL-1 selective inhibitors have advanced to clinical trials. This review briefly discusses recent advances in the development of small molecules targeting MCL-1 for cancer therapy. Keywords: BCL-2, BAX, BAK, apoptosis, BH3 mimeticshttps://www.dovepress.com/mcl-1-inhibition-in-cancer-treatment-peer-reviewed-article-OTTBCL-2BAXBAKapoptosisBH3 mimetics
collection DOAJ
language English
format Article
sources DOAJ
author Xiang W
Yang CY
Bai L
spellingShingle Xiang W
Yang CY
Bai L
MCL-1 inhibition in cancer treatment
OncoTargets and Therapy
BCL-2
BAX
BAK
apoptosis
BH3 mimetics
author_facet Xiang W
Yang CY
Bai L
author_sort Xiang W
title MCL-1 inhibition in cancer treatment
title_short MCL-1 inhibition in cancer treatment
title_full MCL-1 inhibition in cancer treatment
title_fullStr MCL-1 inhibition in cancer treatment
title_full_unstemmed MCL-1 inhibition in cancer treatment
title_sort mcl-1 inhibition in cancer treatment
publisher Dove Medical Press
series OncoTargets and Therapy
issn 1178-6930
publishDate 2018-10-01
description Weiguo Xiang,1 Chao-Yie Yang,1,2 Longchuan Bai1,2 1Department of Internal Medicine, University of Michigan Medical School, 2Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA Abstract: Myeloid cell leukemia-1 (MCL-1), a member of antiapoptotic BCL-2 family proteins, is a key regulator of mitochondrial homeostasis. Frequent overexpression of MCL-1 in human primary and drug-resistant cancer cells makes it an attractive cancer therapeutic target. Significant progress has been made in the development of small-molecule MCL-1 inhibitors in recent years, and three MCL-1 selective inhibitors have advanced to clinical trials. This review briefly discusses recent advances in the development of small molecules targeting MCL-1 for cancer therapy. Keywords: BCL-2, BAX, BAK, apoptosis, BH3 mimetics
topic BCL-2
BAX
BAK
apoptosis
BH3 mimetics
url https://www.dovepress.com/mcl-1-inhibition-in-cancer-treatment-peer-reviewed-article-OTT
work_keys_str_mv AT xiangw mcl1inhibitionincancertreatment
AT yangcy mcl1inhibitionincancertreatment
AT bail mcl1inhibitionincancertreatment
_version_ 1725111735404199936

Similar Items